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Pseudomonas aeruginosa (Pa) is one of the most common and clinically important pathogens in patients with cystic ﬁbrosis (CF). Chronic Pa
colonization in CF patients is associated with increased morbidity and mortality. Pa strains causing early infection are usually antibiotic sensitive
and have low bacterial density in the airways. As a result, the treatment strategy has shifted from suppressive therapy in patients chronically
colonized by Pa to attempts at early eradication therapy as soon as Pa is detected. In the literature, different treatment regimens have been studied.
However, the optimal treatment regimen and duration of treatment are not yet determined.
In this article, an overview on the natural history of early Pa colonization and the history of eradication treatment is given. Moreover, the results
of the different eradication treatment trials and directions for future research are discussed.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Pseudomonas aeruginosa; Eradication; Therapy
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Pseudomonas aeruginosa (Pa) is one of the major pulmonary
pathogens in patients with cystic fibrosis (CF). By adulthood,
80% of the patients are colonized by Pa [1].⁎ Corresponding author. Tel.: +32 93322852.
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http://dx.doi.org/10.1016/j.jcf.2012.07.008lishedThe first Pa colonization episode can occur very early in life.
After a first ever colonization episode, patients may go through
different episodes of colonization (intermittent colonization),
preceding chronic colonization by months to years, eventually
resulting in chronic infection [2–4]. Pa strains causing early
colonization have usually a nonmucoid phenotype, whereas Pa
strains in chronically colonized patients are mucoid and form
biofilms.by Elsevier B.V. All rights reserved.
Table 1
An overview of the different definitions of (chronic) P. aeruginosa
colonization/infection.
European consensus criteria [7]
• Lung colonization by Pa: “Presence of Pa in the bronchial tree without direct
(inflammation, fever, etc.) or indirect (specific antibody response) signs of
infection and tissue damage”
• Chronic lung colonization by Pa: “Presence of Pa in the bronchial tree for at
least 6 months, based on at least three positive cultures with at least one
month intervals between them without direct (inflammation, fever, etc.) or
indirect (specific antibody response) signs of infection and tissue damage”.
• Lung infection by Pa: “Presence of Pa in the bronchial tree with direct
(inflammation, fever, etc.) or indirect (specific antibody response) signs of
infection and tissue damage. Infection can also be diagnosed on the basis of a
positive antibody response in at least two examinations for patients who do
not expectorate and present with negative bacterial cultures”.
• Chronic lung infection by Pa: “Presence of Pa in the bronchial tree for at least
6 months, based on at least three positive cultures with at least one month
intervals between them with direct (inflammation, fever, etc.) or indirect
(specific antibody response) signs of infection and tissue damage. Chronic
infection can also be diagnosed on the basis of a positive antibody response
in at least two examinations for patients who do not expectorate and present
with negative bacterial cultures.”
The Leeds criteria [8] classify CF patients as:
• Never infected by Pa: Pa has never been cultured from sputum or cough
swab.
• Free of Pa infection: no growth of Pa during the previous 12 months, having
previously been Pa culture positive.
• Intermittently infected by Pa: when≤50% of months, when samples had been
taken, Pa cultures are positive.
• Chronically infected by Pa: when N50% of months when samples had been
taken, Pa cultures are positive.
The “Copenhagen criteria” [16]:
• Chronic Pa infection: “Persistent presence of Pa for at least 6 consecutive
months, or less when combined with the presence of two or more Pa
precipitins”.
• Intermittent Pa colonization: “Culture of Pa at least once and the presence of
normal levels of precipitating antibodies against Pa”.
According to Ballmann et al. [17] and Kerem et al. [10] a patient is considered
chronically infected by Pa when having more than 50% of cough swabs or
sputum samples positive in a 12-month period. Fitzsimmons et al. [18]
classified a patient as chronically infected if the last sputum sample of each year
grows Pa.
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and evolution from nonmucoid to mucoid Pa come from
follow-up of CF patients detected through neonatal screening
projects: Li and co-workers [5] prospectively evaluated 56 CF
patients, diagnosed by the Wisconsin CF Neonatal Screening
Project. Nearly one third (29%) acquired nonmucoid Pa
already in the first 6 months of life. Nonmucoid Pa was
acquired at a median age of 1 year and mucoid Pa at a median
age of 13 years.
Without antibiotic treatment for initial Pa colonization,
approximately 20% of the CF patients will become chroni-
cally colonized directly after the first positive culture. The
remainder develops chronic colonization after a median time of
12 months [6].
Unfortunately, comparison of the different studies on
(chronic) colonization by Pa is hampered by the lack of
agreement on the definitions of chronic colonization/infection.
Currently, there is no universally accepted definition and both
terms are often used equivalently in the literature. An overview
of the different criteria is presented in Table 1. Most European
CF centers use the “European consensus criteria” agreed by
Döring et al. [7] or the “Leeds criteria” defined by Lee et al.
[8].
Pa lung colonization in CF patients clearly results in a
poorer clinical outcome, especially when chronically colonized
[9–12]. Acquisition of mucoid Pa is associated with an
accelerated rate of decline in pulmonary function [13].
Pa strains causing early colonization are usually antibiotic
sensitive and have low bacterial density in the airways [2,4].
Aggressive antibiotic treatment of these early infecting strains
often successfully eradicates Pa. As a result, treatment strategy
has shifted from suppressive therapy in patients chronically
colonized by Pa to attempts at early eradication therapy as soon
as Pa is detected [14,15].
2. Eradication therapy for Pa colonization episodes in not
chronically colonized CF patients
The first observations of the favorable effect of eradication
treatment for early Pa isolates date from the eighties and early
nineties.
Littlewood et al. [19] observed that treatment with inhaled
colistin in 7 patients with recent Pa acquisition resulted in a
significant reduction of Pa positive cultures.
Steinkamp et al. [20] treated 28 CF children with recent Pa
colonization with IV anti-pseudomonas antibiotics during
2 weeks. Eighteen (64%) of these patients were free of Pa at the
end of the treatment period. This number gradually declined over
time, leaving just 1 patient (3.5%) free of Pa after 15 months.
Valerius et al. [21] compared treatment with oral ciprofloxacin
and inhaled colistin for 3 weeks with placebo for 3 weeks in 26
CF patients with a new Pa colonization episode. At the end of the
27 month observation period, the treatment group had signifi-
cantly less Pa positive cultures and a significantly lower rate of
chronic colonization.
As a result of these observations, several eradication trials,
studying different treatment regimens, have been undertaken.Initially, the combination of oral ciprofloxacin and inhaled
antibiotics (tobramycin or colistin) for varying time was most
frequently used. The more recent studies also report the value
of inhaled antibiotics (mainly tobramycin) for early eradication.
However, comparison between the different studies is
difficult due to different methodologies, different eradication
treatment regimens, different outcome measures and different
definitions of eradication and chronic colonization and/or chronic
infection.
In the following section, we will discuss both microbiolog-
ical and clinical endpoints of the eradication studies and also
focus on head to head comparative data of treatment regimens.
The topics of eradication of mucoid Pa and genotype based
eradication studies will also be addressed. All eradication trials
are summarized in Table 2. More extensive data from the
eradication trials are available online in Table 3.
Table 2
An overview of the different Pa eradication treatment studies.
Reference Study
design
Number
of patients
Inclusion criteria Antibiotics: dosage/frequency/duration Main outcome measures Main results/remarks
Inhaled antibiotics
Littlewood
[19]
Cohort 7 Recent (median
5 m) Pa pos
cultures
Colomycin: 500,000 U/bid/long term Positive Pa cultures
before and after
treatment
Before: 25/29 (42%)–after:
8/130
(6%)
Wiesemannn
[23]
RCT,
DB, PC
11 TG/
11 PG
Two pos Pa
cultures
TG: tobramycin: 80 mg/bid/12 m Time to conversion
from Pa+ to Pa‐culture
Significantly shorter in TG
than in PG
Neg Pa antibodies PG: placebo/bid/12 m Pa eradication at end
of study
TG: 8/9, PG 1/5
Neg Pa cultures
during previous
12 m
Ratjen [24] Cohort 15 Two pos Pa
cultures
Tobramycin: 80 mg/bid/12 m Eradication of Pa 14/15 patients free of Pa
(culture+serology) at 12 and
24 m
Neg Pa antibodies
Neg Pa cultures
previously
Gibson [25] RCT,
DB, PC
21 Pos Pa culture from
BAL andOP at entry
TG: tobramycin 300 mg/bid/28 d Lower airway Pa
eradication (BAL d28)
TG: 8/8 (100%) vs PG: 1/13
(8%)
Pos Pa culture
during previous
12 m
PG: placebo/bid/28 d Recurrence of Pa (OP
culture)
TG: 1/8 on d42–2/8 on d56
Gibson [26] Cohort 31 Pos Pa culture from
BAL and OP at
entry
Tobramycin: 300 mg/bid/28 or 56 d Lower airway Pa
eradication (BAL)
23/31 patients (74%); c1: 6/8;
c2: 5/8; c3: 9/11; c4: 3/4
c1:28/
56 a
Pos Pa culture
during previous
12 m
Pa eradication (OP
culture on same day as
BAL culture)
22/31 patients (71%); c1: 5/8;
c2: 4/8; c3: 8/10; c4: 5/5
c2:28/
84 a
c3:56/
112 a
c4:28/
112 a
IV antibiotics
Steinkamp
[20]
Cohort 28 Recent (median
5 m) Pa pos
cultures
Azlocillin: 150 mg/kg/d/14 d Eradication of Pa 18/28 (64.2%) during
treatment;
+ tobramycin: 10–15 mg/kg/d/14 d 10/28 (35.7%) at 3 m; 5/28
(17.9%) at 6 m; 1/28 (3.6%)at
32 m
Inhaled oral antibiotics
Valerius
[21]
RCT 14 TG, 12
PG
Pos Pa sputum
cultures
TG: ciprofloxacin/250–750 mg/bid/
3 w
Development of chronic
Pa infection b
TG: 2/14 (14%) vs PG: 7/12
(58%) (pb0.05)
No chronic Pa
infection b
+inh colistin/1 MU/bid/3 w Positive Pa cultures TG: 49/214 (23%) vs PG: 64/
158 (41%) (p=0.0006)
Never anti
pseudomonas
antibiotics before
PG: no treatment
Vazquez
[22]
Cohort 8+8 HC First ever Pa pos
culture
Ciprofloxacin/30–40 mg/kg/day/2 w Positive Pa cultures TG: 49/214 (4.6%) vs HC:
109/120 (86%) (pb0.001)
HC Neg Pa
precipitins
+inh colistin 1 MU+tobramycin
100 mg/bid/long-term
HC: first ever Pa
before start study,
no treatment
Frederiksen
[37]
Cohort 91 (48
TG, 43
HC)
Pos Pa culture (first
ever or intermittent)
1st Pa: ciprofloxacin 25–50 mg/kg/d/
3 w+inh colistin 1 MU/bid/3 w
Development of chronic
Pa infection b
TG: 7/48 (15%) vs HC: 19/43
(44%)
(continued on next page)
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Table 2 (continued)
Reference Study
design
Number
of patients
Inclusion criteria Antibiotics: dosage/frequency/duration Main outcome measures Main results/remarks
HC HC: pos Pa
cultures
before study, no
treatment
2nd Pa: ciprofloxacin 25–50 mg/kg/
3w+inh colistin 2 MU/tid/3 w
Kaplan–Meier estimate: TG:
16% vs HC: 72% over 3.5 y
(pb0.005)
≥3rd Pa: ciprofloxacin 25–50 mg/kg/
3 m+inh colistin
2 MU/tid/3 m
Tacetti [27] Cohort 58 First ever Pa pos
culture
Step 1: ciprofloxacin: 30 mg/kg/d/
3w+inh colistin 1–2 MU/bid/3 w
Eradication of Pa c 47/58 (81%)
Step 2: if persistence after step 1:
ciprofloxacin 15 mg/kg/bid
Recurrence of Pa; Pa free
time period
24/47 (51%); median 18 m
(range 4–80 m)
+inh colistin 2 MU/tid/3 w
Step 3: if persistence after step 2:
treatment continued for 3 m
Hansen [38] Cohort 146 Pos Pa cultures
(first ever or
intermittently)
b1996: see Frederiksen [37] Development of chronic
Pa infection b
12/99 (12%) chronic
infection after median
time 3.7 y (0.5–10.3 y)
HC (99/146
first ever
Pa)
N1996: ciprofloxacin 25–50 mg/kg/d/
3 m+inh colistin 2 MU/tid/3 m
Pa-free time interval No treatment: 1.9 m
(0–58.3 m); 3 w
treatment: 5 m; 3 m
treatment: 10.4 m
(ss no treatment vs treatment)
Schelstraete
[28]
Cohort 41 First ever Pa pos
culture
Oral ciprofloxacin 30 mg/kg/d/3 m+inh
colistin 2 MU/bid/3 m
Eradication of Pa d 34/41 (83%)
Recurrence of Pa; median
time to recurrence of Pa
18/34 (53%); 7.5 m (2–
55 m)
Median Pa free time
period
0 m in CC patients vs 7 m in
IC patients
(pb0.05)
Miscellaneous
Munck [29] Cohort 19 Pos Pa culture IV ceftazidim: 300 mg/kg/d/18–21 d or
imipenem:75 mg/kg/d/18–21 d
Eradication of Pa e 19/19 (100%)
Neg Pa precipitins +tobramcin: 7.5 mg/kg/d/18–21 d Recurrende of Pa;
median time to
recurrence of Pa
19/19; 8 m (3–25 m)
Followed by inhaled colistin/1–3 MU/
NR/N2 m
Nixon [9] Cohort 24 Pos Pa culture IV ticarcillin–clavulanic acid/NR/
2w+tobramycin/NR/2 w
Eradication of Pa f 6/24 (25%)
(13 patients mucoid
Pa at first
detection)
Followed by oral ciprofloxacin/NR/3 m
and/or inh tobramycin/NR/3 m
Griese [30] Cohort 16 First ever Pa pos
culture
b5 y: inh tobramycin 80 mg/bid/4 w Eradication of Pa g 14/16 (88%)
(confirmed by
second pos culture)
N5 y: ciprofloxacin/NR/
3 w+inhaled colistin 1 MU/bid/3 w
In some patients also IV
ceftazidim/NR/NR+tobramycin/NR/NR
Douglas
[31]
Cohort 26 Pos Pa culture in
BALf
IV ticarcillin–clavulanate/300 mg/kg/d/
14 d or ceftazidim/150 mg/kg/d/14 d
Eradication of Pa h 23/26 (88.5%)
(6/33 patients
mucoid Pa at
detection)
+IV tobramycin 7.5 mg/kg/d/14 d Recurrence of Pa 3/23 (13%) recurrence after
resp 12.33 and 37 m
Followed by oral ciprofloxacin/10 mg/
kg/bid/28 d
And inh tobramycin/80 mg/bid/28 d
Comparison of therapies
Proesmans
[32]
RCT 58 Pos Pa iculture TG1:inh tobramycin: 300 mg/bid/28 d Eradication of Pa d TG1: 23/29 (79.3%) vs TG2:
26/29 (89.7%) (p=0.47)
(first ever or after
N6 m absence of
Pa)
TG2: oral ciprofloxacin:30 mg/
kg/d/3 m+inh colistin 2 MU/bid/3 m
Median time to
recurrence of Pa
TG1: 5 m vs TG2: 9 m (p=
0.608)
4 P. Schelstraete et al. / Journal of Cystic Fibrosis 12 (2013) 1–8
Table 2 (continued)
Reference Study
design
Number
of patients
Inclusion criteria Antibiotics: dosage/frequency/duration Main outcome measures Main results/remarks
(18/58 first ever
Pa)
Eradication of Pa at 6 m TG1: 13/29 (44.8%) vs TG2:
19/29(65.5%)
Pa chronic colonization
(Leeds criteria) at 1 and
2 y
1 y: 3/58 (5%) 2 y: 5/47
(10%)
Tacetti [36] RCT TG1: 105 Pos Pa culture TG1: oral ciprofloxacin: 30 mg/kg/d/
28 d+ inh colistin 2 MU/bid/28 d
Eradication of Pa i TG1: 66/105 (62.8%) vs
TG2: 77/118 (65.2%)
TG2: 118 (first ever or after
N6 m absence of
Pa)
TG2: oral ciprofloxacin:30 mg/
kg/d/28 d+inh tobramycin
300 mg/bid/28 d
Pa free at m2 TG1: 84/105 (80%) vs TG2:
92/118 (77.9%)
(54.3% first ever
Pa)
Pa free at m4 TG1: 69/105 (65.7%) vs
TG2: 80/118 (67.8%)
Treggiari
[33]
RCT 304 Pos Pa culture
(b6 m prior to
study inclusion)
Or cycled AB/3 m regardless of culture
results
% pos Pa cultures b20% at each time point of the
study
(EPIC trial) (first ever Pa or
after N2 y absence
of Pa)
*inh tobramycin: 300 mg/bid/28d+oral
ciprofloxacin: 15–20 mg/kg/bid/14 d
vs *inh tobramycin: 300 mg/bid/
28 d+oral placebo 14 d
or culture-based AB:AB in case of
positive Pa culture
*inh tobramycin:300 mg/bid/
28 d+oral ciprofloxacin:15–20 mg/kg/
bid/14 d
vs *inh tobramycin: 300 mg/bid/
28 d+oral placebo 14 d
Ratjen [34] RCT 65 First ever Pa pos
culture
TG 1: inh tobramycin: 300 mg/bid/28 d Median time to
recurrence Pa j
TG 1: 26.12 m, TG 2:
25.82 m (ns)
ELITE trial New Pa pos culture
(after 4 neg cultures
N1 y)
TG 2: inh tobramycin: 300 mg/bid/56 d Proportion of patients
free of Pa
TG 1 and TG 2: N90% 1 m
after end of
therapy; TG1: 27/41 (66%),
TG 2: 25/36
(69%) at end of the study
Neg Pa antibodies
Abbreviations:
AB: antibiotic(s)
BAL(f): broncho-alveolar lavage (fluid)
bid: bis in die (two times a day)
CC: chronically colonized
d: day(s)
DB: double blind
HC: historic control
IC: intermittently colonized
IV: intravenous
m: month(s)
NBS: newborn screening
NR: not reported
ns: statitistically not significant
Pa: Pseudomonas aeruginosa
PC: placebo controlled
PG: placebo group
pos: positive
RCT: randomized controlled trial
resp: respiratory
ss: statistically significant
TB: triple blind
tid: ter in die (three times a day)
TG: treatment group
U: unit(s)
vs: versus
w: week(s)
y: year(s)
a cx: xx/xx = cohort x: days of treatment/BAL at day x.
b Chronic Pa infection: “presence of Pa in monthly routine sputum specimens for six consecutive months and/or the development of precipitating serum antibodies
against Pa”.
c Eradication: ≥3 consecutive neg Pa cultures and neg Pa antibodies within 6 m treatment.
d Eradication: neg Pa culture at the end of the treatment.
e Eradication not deﬁned.
f Eradication: absence of Pa in BAL or sputum for N12 months.
g Eradication: negative cultures and negative Pa antibodies for N24 m.
h Eradication: neg culture in BAL 3 m after detection.
i Eradication: ≥3 neg Pa cultures over 6 months.
j Eradication: neg BAL cultures 2 w after end of oral therapy+3 subsequent negative sputum cultures.
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• Studies on microbiological effect: eradication, recurrence of
Pa and time to recurrence
Whatever early eradication treatment is used, all trials report
successful eradication and/or significantly less Pa positive
cultures during treatment [19,21–23]. The more recent
eradication trials (2000–2012) also report percentages of
eradication immediately after or within 6 months after
treatment, the majority varying between 80% and 100%
[24–35], except for Nixon et al. (25% eradication) [9] and
Taccetti et al. (65% eradication) [36].
In 12% [31] to 100% [29] of the patients Pa recurs after a
median time period from 7.5 to 26 months.
• Studies on delay in chronic infection
The Danish group reported that only 12 of the 99 patients
(12%) with a first ever Pa isolate developed chronic
infection after a median time of 3.7 years, compared to
72% of the historic control patients. Up to 80% of the
patients were protected against development of chronic
infection for up to 15 years, according to the Kaplan–Meier
estimate [37,38].
3.1. Early eradication trials with clinical endpoints
In view of the deleterious effect of chronic Pa on the clinical
outcome of CF patients, it seems logical that preventing or
delaying chronic infection should have an advantageous effect on
clinical parameters. However, data on the effect of eradication
therapy on clinical parameters are currently scarce. This may be
due to the short observation time in most studies. Steinkamp et al.
[20] reported a significantly better weight gain immediately after
intravenous antibiotic treatment.
Frederiksen et al. [37] demonstrated a favorable effect on
lung function parameters, whereas others [20,23,30,34] did not.
Recently, Mayer-Hamblett [35] and colleagues demonstrated
that the children included in the EPIC trial who failed to
eradicate Pa after initial antibiotic treatment are at higher risk of
subsequent exacerbation, suggesting clinical benefit of a
successful early Pa eradication.
3.2. Head-to-head comparison of different treatment regimens
Up till now, only 4 studies compared the efficacy of different
treatment strategies/treatment duration for eradication of Pa.
None of them detected a statistically significant difference in
eradication [32–34,36].
It is worth noting that the Danish group changed their early
treatment policy to a 3 month instead of a 3 week antibiotic
treatment after noticing a (statistically not significant) trend
to longer Pa free time period in the 3 month treatment
strategy [38].
3.3. Is eradication of mucoid Pa strains possible?
It is often stated that mucoid strains ofPa cannot be eliminated
from the lower airways. However, recent studies contradict thistheorem. Gibson et al. [25] reported eradication of both
nonmucoid and mucoid Pa with inhaled tobramycin. In a UK‐
based study [39], 57.8% of the patients with mucoid Pa cleared
this organism for more than 1 year and 32.8% remained Pa free
for a median time of 55 months after antibiotic treatment.
Recently, Troxler et al. [40] observed clearance of mucoid Pa in
73.3% of patients undergoing eradication attempt, compared to
only 36.6% of the non-treated patients (pb0.05).
3.4. Does early eradication treatment result in eradication or
suppression of Pa?
This question on eradication versus suppression can only be
answered by studying the initial Pa genotypes and comparing
them with the genotypes of subsequent Pa isolates. These data
however are scarce and provide conflicting results.
Whereas in some studies the majority of the patients are
colonized by a genetically different strain in subsequent Pa
colonization episodes [29,36], suggesting that eradication
therapy really eradicated the initial Pa, others revealed the
opposite [26,28,34]. The latter studies suggest that Pa
recurrence is caused by a regrowth of partially suppressed Pa
or by acquisition from the same (environmental?) source.
4. Discussion
Since the first reports on the advantageous effect of early
antibiotic treatment for Pa colonization episodes in not chroni-
cally colonized patients, several “early eradication studies” have
been carried out. The majority of these studies report an 80 to
100% eradication success rate with a median time to Pa
recurrence of 7.5 to 26 months. Moreover, the Danish data
demonstrated that early eradication therapy postpones the onset of
chronic colonization. Although previously considered to be
impossible, recent reports showed that mucoid Pa can also be
eradicated from the CF airways. Relying on these observations
and trials, the use of eradication treatment for Pa in not
chronically colonized/infected patients has become common
clinical practice. Nevertheless, questions remain on the optimal
way of administration of antibiotics (intravenous/oral/inhalation
or combinations) and the optimal treatment duration for long
lasting eradication.
There is no significant evidence that IV treatment is the
optimal treatment regimen. Although Munck et al. reported a
100% eradication after intravenous antipseudomonal treatment,
all patients reacquired Pa after a median time of 8 months. The
less successful eradication results of Nixon et al. [9] can
presumably be explained by late diagnosis using annual BAL
for detection and by the high number of mucoid Pa. The late
onset of IV treatment (1–11 months, median time 5 months
after detection of Pa) in the study of Steinkamp et al. [20] might
have negatively affected the eradication success.
Comparative studies have not defined a superior treatment
option until now, neither has a longer or combination treatment
period proven to be superior. This fact is also important from
the patient's point of view: a reduced treatment intensity
possibly enhances treatment adherence and diminishes the risk
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tobramycin during 56 days was not superior to 28 days. In the
EPIC trial combined treatment of oral ciprofloxacin and inhaled
tobramycin was not more effective than monotherapy with
inhaled tobramycin. Adding oral ciprofloxacin during a 2-week
period might probably be too short to detect any differences. In
the “Danish experience”, using oral ciprofloxacin and inhaled
colistin, a non-significant trend for a prolonged Pa free period
was observed in 3 months (10.4 months) compared to the
3 week regimen (5 months). Nevertheless, this observation led
to a change in early treatment policy favoring a 3 month
regimen [38]. The open study of Proesmans and colleagues [32]
compared two widely used but totally different eradication
schedules (inhaled tobramycin during 28 days versus oral
ciprofloxacin and inhaled colistin for 3months). No statistical
differences in eradication neither in recurrence of positive
cultures could be detected. Unfortunately, the study was
underpowered.
Another unanswered question is whether antibiotic therapy
really eradicates the initial Pa or only results in a temporary
reduction of the bacterial load, escaping the sensitivity of the
detection techniques. This question on eradication versus
suppression can only be addressed by studying the initial Pa
genotype and comparing this with the genotype of subsequent
Pa isolates. A few studies, addressing this topic, provide
conflicting results with 25 to 75% of the patients being
colonized by an identical genotype in a subsequent colonization
episode after what initially was considered a successful
eradication. Moreover, the presence of an identical Pa isolate
in a subsequent Pa colonization episode proved to be an
ominous sign for impending chronic colonization [28].
Genotyping of Pa is essential in the evaluation of the efficacy
of eradication treatment and should be included in each future
eradication trial.
Remarkably, a similar rate of eradication failures (10–20%)
is noticed in many clinical studies with widely varying
schedules of antipseudomonal antibiotics. This can partially
be explained by the different inclusion criteria (first ever versus
previous Pa), different methodology, different definitions of
eradication and/or Pa free time period and different follow-up
times, the latter especially influencing recurrence rates. Even
when only considering eradication results for a first ever Pa
episode, no 100% eradication is achieved. Patient factors
possibly contributing to eradication failure include therapy
compliance, delay in detection of Pa (in most centers only
quarterly respiratory cultures are taken) and the use of
insensitive detection methods (culture on oral swabs or
nasopharyngeal aspirates used in young, non sputum expecto-
rating children with first Pa colonization episodes). Further-
more, the hypermutability of Pa itself, with rapid development
of resistant organisms and more difficult eradicating mucoid Pa
phenotypes might account for eradication failure.
5. Conclusions
All the different studies on eradication treatment of the first
ever colonization of Pa agree on the favorable effect ofantibiotics on eradication of Pa, on the recurrence frequency of
positive Pa cultures and on the delay in onset of chronic
infection. Early treatment of Pa colonization/infection episodes
is now considered the standard of care in CF centers. Recent
studies have demonstrated that even mucoid Pa can be
eradicated. Head-to-head comparison of different treatment
regimens has until now been unable to define a superior
treatment regimen. Larger head-to-head comparative studies
are needed to determine the optimal treatment regimen and
duration of eradication treatment. Ideally, every study on
eradication treatment and those comparing treatment regimens
should include genotypic characterization of Pa.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2012.07.008.References
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